Blood test distinguishes recurrent breast cancer in study

A vial of blood may carry more than traces of a tumor’s mutations. At Kumamoto University, a research team led by Associate Professor Sugiko Watanabe and Professor Mitsuyoshi Nakao studied whether the way DNA is packaged could help distinguish recurrent breast cancer from primary disease. Their analysis covered 150 breast cancer samples, including 45 from recurrent or metastatic disease.

The method focuses on cell-free DNA (cfDNA), tiny DNA fragments circulating in the bloodstream. Instead of reading only changes in the DNA sequence, the researchers examined nucleosomes: structures in which DNA is wrapped around histone proteins. Their arrangement reflects how genes are regulated and how tightly or openly sections of DNA are packaged, leaving blood-derived fragments with clues about what is happening inside cancer cells.

The team targeted 26 genomic regions known to undergo transcriptional changes when breast cancer cells develop resistance to hormone therapy. Recurrent breast cancer was linked to more genetic variants and shorter cfDNA fragments. Two regions, RERE and SYNPO2, produced a nucleosome-based score with an AUC of 0.826, meaning the score separated primary and recurrent disease effectively within this study. Combining nucleosome data with other cfDNA features through machine learning improved prediction further.

And so what, concretely? If larger studies confirm the signal, a blood sample could eventually help clinicians monitor patients during and after treatment without relying only on more invasive approaches. It could support earlier detection of recurrence and more tailored treatment decisions. That is a possible use, not an available service: the researchers say the approach still needs validation in broader clinical settings.

The main constraint is the evidence base. The study used a relatively limited retrospective cohort, and differences in breast cancer subtypes and patient backgrounds between the groups may affect how broadly the result applies. Prospective studies with larger populations will be needed before the test can be established in clinical practice.